JP7086942B2 - Gpr120モジュレーターとして有用な単環式化合物 - Google Patents

Gpr120モジュレーターとして有用な単環式化合物 Download PDF

Info

Publication number
JP7086942B2
JP7086942B2 JP2019513935A JP2019513935A JP7086942B2 JP 7086942 B2 JP7086942 B2 JP 7086942B2 JP 2019513935 A JP2019513935 A JP 2019513935A JP 2019513935 A JP2019513935 A JP 2019513935A JP 7086942 B2 JP7086942 B2 JP 7086942B2
Authority
JP
Japan
Prior art keywords
compound
lcms
esi
nmr
synthesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019513935A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019530674A5 (https=
JP2019530674A (ja
Inventor
ブライアン ライムンド,
エレナ エス. コルタン,
ジョン グリフィン,
エリック ステインジェランド,
Original Assignee
インテグラル ヘルス, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インテグラル ヘルス, インコーポレイテッド filed Critical インテグラル ヘルス, インコーポレイテッド
Publication of JP2019530674A publication Critical patent/JP2019530674A/ja
Publication of JP2019530674A5 publication Critical patent/JP2019530674A5/ja
Application granted granted Critical
Publication of JP7086942B2 publication Critical patent/JP7086942B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019513935A 2016-09-12 2017-09-11 Gpr120モジュレーターとして有用な単環式化合物 Active JP7086942B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662393616P 2016-09-12 2016-09-12
US62/393,616 2016-09-12
PCT/US2017/050956 WO2018049324A1 (en) 2016-09-12 2017-09-11 Monocyclic compounds useful as gpr120 modulators

Publications (3)

Publication Number Publication Date
JP2019530674A JP2019530674A (ja) 2019-10-24
JP2019530674A5 JP2019530674A5 (https=) 2020-11-12
JP7086942B2 true JP7086942B2 (ja) 2022-06-20

Family

ID=61562455

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019513935A Active JP7086942B2 (ja) 2016-09-12 2017-09-11 Gpr120モジュレーターとして有用な単環式化合物

Country Status (7)

Country Link
US (3) US10800773B2 (https=)
EP (1) EP3509587B1 (https=)
JP (1) JP7086942B2 (https=)
KR (1) KR102537985B1 (https=)
CN (1) CN110225752B (https=)
CA (1) CA3041033A1 (https=)
WO (1) WO2018049324A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018049324A1 (en) 2016-09-12 2018-03-15 Numerate, Inc. Monocyclic compounds useful as gpr120 modulators
EP3509588B1 (en) * 2016-09-12 2023-06-07 Integral Health,Inc. Bicyclic compounds useful as gpr120 modulators
AU2019255363A1 (en) * 2018-04-20 2020-11-05 Krish Biotech Research Private Limited Method of treatment of non-alcoholic steatohepatitis, nash
US11142525B2 (en) * 2018-11-15 2021-10-12 Pfizer Inc. Azalactam compounds as HPK1 inhibitors
CN115698004A (zh) 2020-05-01 2023-02-03 辉瑞公司 作为hpk1抑制剂的氮杂内酰胺化合物
IL297600A (en) * 2020-05-08 2022-12-01 Georgiamune Llc modulators of akt3
CN114671827B (zh) * 2020-12-24 2024-09-20 杭州百新生物医药科技有限公司 邻苯甲酰磺酰亚胺类衍生物及其应用
KR102605163B1 (ko) * 2021-06-01 2023-11-23 연세대학교 산학협력단 뇌암의 예방 또는 치료용 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008066131A1 (en) 2006-12-01 2008-06-05 Banyu Pharmaceutical Co., Ltd. Novel phenyl-isoxazol-3-ol derivative
WO2009147990A1 (ja) 2008-06-02 2009-12-10 萬有製薬株式会社 新規イソオキサゾール誘導体
JP2010519258A (ja) 2007-02-22 2010-06-03 アイアールエム・リミテッド・ライアビリティ・カンパニー Gタンパク質共役受容体のモジュレーターとしてのチアゾール誘導体
JP2014533736A (ja) 2011-11-30 2014-12-15 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 新規二環式ジヒドロイソキノリン−1−オン誘導体
JP2016141618A (ja) 2015-01-29 2016-08-08 国立大学法人金沢大学 脱水縮合剤

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2735225A (en) * 1956-02-21 Table ix p petri dish tests with x-phthalimido-
DE2253251A1 (de) 1972-10-30 1974-05-09 Thomae Gmbh Dr K Neue phthalimido-sulfonylharnstoffe
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US4165435A (en) * 1976-06-25 1979-08-21 Ciba-Geigy Corporation Fire retardant s-triazine derivatives
DE3474547D1 (en) 1983-12-02 1988-11-17 Shell Int Research Diphenyl ether herbicides
FR2659327A1 (fr) * 1990-03-08 1991-09-13 Centre Nat Rech Scient Derives du benzisothiazolinone-1-dioxyde, utilisables comme inhibiteurs des elastases.
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5350761A (en) 1991-07-30 1994-09-27 Ciba-Geigy Corporation Indolyl substituted hydroxylamine derivatives
EP0526402B1 (en) 1991-07-30 1998-01-21 Novartis AG Heteroaryl substituted hydroxylamine derivatives as lipoxygenase inhibitors
TW219935B (https=) 1991-12-25 1994-02-01 Mitsubishi Chemicals Co Ltd
PT891332E (pt) * 1996-03-29 2004-07-30 Pfizer Derivados de 6-fenilpiridil-2-amina
US6716836B2 (en) 2001-03-22 2004-04-06 Boehringer Ingelheim (Canada) Ltd. Non-nucleoside reverse transcriptase inhibitors
GB0124627D0 (en) 2001-10-15 2001-12-05 Smithkline Beecham Plc Novel compounds
DE10348022A1 (de) 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
CA2547430A1 (en) 2003-11-26 2005-06-09 Takeda Pharmaceutical Company Limited Receptor function regulating agent
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
WO2006038594A1 (ja) 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. N型カルシウムチャネル阻害薬
US8110681B2 (en) 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
RU2455302C2 (ru) 2006-12-27 2012-07-10 Санофи-Авентис ЗАМЕЩЕННЫЕ ИЗОХИНОЛИНОВЫЕ И ИЗОХИНОЛИНОНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Rho-КИНАЗЫ
JP5175866B2 (ja) 2007-02-22 2013-04-03 アイアールエム・リミテッド・ライアビリティ・カンパニー Gタンパク質共役受容体を調節するための化合物および方法
JP5420400B2 (ja) 2007-04-26 2014-02-19 国立大学法人京都大学 Gタンパク質共役型レセプター作動剤
US8569378B2 (en) 2007-07-20 2013-10-29 Toshiyuki Sakai p27 protein inducer
NZ592603A (en) 2008-10-21 2013-02-22 Metabolex Inc Aryl gpr120 receptor agonists and uses thereof
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
EP2406248B1 (en) * 2009-03-11 2013-12-25 Msd K.K. Novel isoindolin-1-one derivative
US8314120B2 (en) 2010-03-30 2012-11-20 Abbott Gmbh & Co. Kg Small molecule potentiators of metabotropic glutamate receptors
JP5746334B2 (ja) 2010-06-16 2015-07-08 シマベイ セラピューティクス, インコーポレーテッド Gpr120受容体作動薬及びその使用
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
CA2841757A1 (en) * 2011-07-15 2013-01-24 Etzer Darout Gpr 119 modulators
WO2013139341A1 (en) 2012-03-20 2013-09-26 Syddansk Universitet Gpr120 receptor modulators
EP2906542B1 (en) 2012-10-11 2019-08-07 Merck Sharp & Dohme Corp. Substituted spiropiperidinyl compounds useful as gpr120 agonists
KR101942752B1 (ko) 2012-11-05 2019-01-28 주식회사 엘지화학 Gpr120 효능제로서의 티오아릴 유도체
CA2893239A1 (en) 2012-12-03 2014-06-12 F. Hoffmann-La Roche Ag Substituted triazole and imidazole compounds
WO2014096941A1 (en) 2012-12-20 2014-06-26 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
CN105209446A (zh) 2013-03-14 2015-12-30 詹森药业有限公司 用于治疗ii型糖尿病的gpr120激动剂
CN105189439B (zh) 2013-03-14 2017-12-29 百时美施贵宝公司 二环[2.2.1]酸gpr120调节剂
CN105008345A (zh) 2013-03-14 2015-10-28 詹森药业有限公司 可用作gpr120的激动剂的双环吡咯衍生物
US8962660B2 (en) 2013-03-14 2015-02-24 Bristol-Myers Squibb Company Oxabicyclo [2.2.2] acid GPR120 modulators
WO2014159061A2 (en) 2013-03-14 2014-10-02 Janssen Pharmaceutica Nv Benzo-fused heterocyclic derivatives useful as agonists of gpr120
WO2014209034A1 (en) * 2013-06-27 2014-12-31 Lg Life Sciences Ltd. Biaryl derivatives as gpr120 agonists
AR099937A1 (es) * 2014-04-04 2016-08-31 Sanofi Sa Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
DK3140296T3 (en) * 2014-05-07 2018-07-23 Bristol Myers Squibb Co PYRROLIDIN GPR40 MODULATORS FOR TREATMENT OF DISEASES SUCH AS DIABETES
EP3186241B1 (en) 2014-08-29 2020-10-07 CHDI Foundation, Inc. Probes for imaging huntington protein
EP3365334B1 (en) 2015-10-21 2024-07-17 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
EP3509588B1 (en) 2016-09-12 2023-06-07 Integral Health,Inc. Bicyclic compounds useful as gpr120 modulators
WO2018049324A1 (en) * 2016-09-12 2018-03-15 Numerate, Inc. Monocyclic compounds useful as gpr120 modulators

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008066131A1 (en) 2006-12-01 2008-06-05 Banyu Pharmaceutical Co., Ltd. Novel phenyl-isoxazol-3-ol derivative
JP2010519258A (ja) 2007-02-22 2010-06-03 アイアールエム・リミテッド・ライアビリティ・カンパニー Gタンパク質共役受容体のモジュレーターとしてのチアゾール誘導体
WO2009147990A1 (ja) 2008-06-02 2009-12-10 萬有製薬株式会社 新規イソオキサゾール誘導体
JP2014533736A (ja) 2011-11-30 2014-12-15 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 新規二環式ジヒドロイソキノリン−1−オン誘導体
JP2016141618A (ja) 2015-01-29 2016-08-08 国立大学法人金沢大学 脱水縮合剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Archiv der Pharmazie,2016年,349(3),P.175-185,(2016年1月13日)
REGISTRY(STN)[online],2011.10.07~2016.06.20[検索日2021.03.01],CAS登録番号1935530-23-6, 1440520-62-6, 1334634-35-3

Also Published As

Publication number Publication date
CA3041033A1 (en) 2018-03-15
WO2018049324A1 (en) 2018-03-15
KR102537985B1 (ko) 2023-05-30
US12116362B2 (en) 2024-10-15
US20230183231A1 (en) 2023-06-15
JP2019530674A (ja) 2019-10-24
EP3509587C0 (en) 2023-12-06
CN110225752B (zh) 2023-05-05
KR20190067174A (ko) 2019-06-14
EP3509587A4 (en) 2020-03-11
US10800773B2 (en) 2020-10-13
US11548886B2 (en) 2023-01-10
CN110225752A (zh) 2019-09-10
US20190202821A1 (en) 2019-07-04
US20210101896A1 (en) 2021-04-08
EP3509587A1 (en) 2019-07-17
EP3509587B1 (en) 2023-12-06

Similar Documents

Publication Publication Date Title
JP7086942B2 (ja) Gpr120モジュレーターとして有用な単環式化合物
JP7065081B2 (ja) Gpr120モジュレーターとして有用な二環式化合物
US20070149547A1 (en) Bipyridyl amides as modulators of metabotropic glutamate receptor-5
JP2009533410A (ja) Gタンパク質共役型受容体(gpr119)アゴニストとしてのアゼチジン誘導体
US10369146B2 (en) Phenyl linked quinolinyl modulators of RORγt
CN1411456A (zh) 结合趋化因子受体的杂环化合物
KR20150070348A (ko) RoRγt의 헤테로아릴 결합 퀴놀리닐 조절제
CN116438174B (zh) 化合物及其作为mif抑制剂的用途
US20250179017A1 (en) Carboxamide compounds as pge2 receptor antagonists
TW202239416A (zh) 含硼之吡唑化合物、包含彼等之組合物及其方法及用途
KR20230061482A (ko) 인터페론 유전자 자극제 (stimulator of interferon genes)(STING) 의 작용제들
KR20160068948A (ko) RORyt의 이차 알코올 퀴놀리닐 조절제
CA3041038C (en) Bicyclic compounds useful as gpr120 modulators
HK40005332A (en) Monocyclic compounds useful as gpr120 modulators
HK40005332B (en) Monocyclic compounds useful as gpr120 modulators
EP4171569A1 (en) Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof
HK40005335A (en) Bicyclic compounds useful as gpr120 modulators
HK40005335B (en) Bicyclic compounds useful as gpr120 modulators

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20200902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200910

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210929

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220120

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220520

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220608

R150 Certificate of patent or registration of utility model

Ref document number: 7086942

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250